<- Go Home
Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.
Market Cap
$67.2M
Volume
181.6K
Cash and Equivalents
$12.1M
EBITDA
$8.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$76.0M
Profit Margin
62.34%
52 Week High
$0.95
52 Week Low
$0.44
Dividend
N/A
Price / Book Value
1.38
Price / Earnings
43.62
Price / Tangible Book Value
1.59
Enterprise Value
$70.5M
Enterprise Value / EBITDA
8.84
Operating Income
$3.3M
Return on Equity
3.95%
Return on Assets
2.37
Cash and Short Term Investments
$12.1M
Debt
$15.4M
Equity
$48.6M
Revenue
$121.9M
Unlevered FCF
$18.2M
Sector
Health Care Equipment and Supplies
Category
N/A